Physician profile
James S Pezzi
NPI 1053339119
$15,375.37
in general payments reported to CMS, 2019-2025
40 companies · $2,704 in 2025
The $2,704 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,859 · 2020: $1,488 · 2021: $2,290 · 2022: $2,107 · 2023: $2,635 · 2024: $2,293 · 2025: $2,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,449 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,449.27 |
| Education | $182.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,079.11 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,199.36 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,578.72 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,151.99 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $592.71 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $493.11 | 2022-2025 | |
| Pfizer INC. | $324.04 | 2019-2025 | |
| Gilead Sciences, INC. | $300.20 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $291.96 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $273.91 | 2023-2025 | Voquezna |
| Celgene Corporation | $249.34 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $240.93 | 2019-2025 | Suflave |
| Intercept Pharmaceuticals, INC. | $227.48 | 2020-2024 | Ocaliva |
| Ucb, INC. | $226.04 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $223.63 | 2019-2024 | Rebyota |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $217.38 | 2024-2025 | Omvoh, Zepbound |
| Nestle Healthcare Nutrition INC. | $197.66 | 2020-2023 | |
| Ardelyx, INC. | $194.76 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $142.28 | 2021-2024 | Dificid, Zinplava |
| Madrigal Pharmaceuticals | $134.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $133.13 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $129.52 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $112.06 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $100.49 | 2021 | |
| Allergan, INC. | $76.12 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $69.96 | 2021 | |
| Organon LLC | $56.79 | 2022-2024 | Renflexis, Hadlima |
| Romark Laboratories, Lc | $45.78 | 2019 | |
| Evoke Pharma, INC. | $42.95 | 2022-2025 | Gimoti |
| Shire North American Group INC | $42.32 | 2019 | |
| Redhill Biopharma INC. | $42.30 | 2020-2021 | |
| Celltrion USA INC. | $40.39 | 2025 | Vegzelma |
| Shionogi INC | $29.17 | 2019 | |
| Novo Nordisk INC | $23.96 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $18.23 | 2023 | Idacio |
| Conmed Corporation | $16.77 | 2019 | |
| Urgo Medical North America, LLC | $15.25 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Amgen INC. | $14.29 | 2023 | Amjevita |
| Ipsen Biopharmaceuticals, INC | $13.66 | 2025 | Iqirvo |
| Echosens North America, INC. | $13.13 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pezzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.